Reported 2 days ago
Leerink Partners has reaffirmed its positive outlook on Travere Therapeutics (NASDAQ:TVTX), rating it as a Buy with a target price of $42. The firm’s confidence is bolstered by the full approval of Travere's product, Filspari, for IgA nephropathy in 2023, which has improved its market position despite anticipated competition. Additionally, opportunities for expanding into focal segmental glomerulosclerosis are currently under FDA review, further enhancing the company's growth prospects.
Source: YAHOO